GlassScriptPhysician profile
Benjamin H Lowentritt
NPI 1578584959
$548,994.12
in general payments reported to CMS, 2019-2025
61 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $77K · 2021: $81K · 2022: $110K · 2023: $56K · 2024: $49K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $80K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Food and Beverage: $16K · Travel and Lodging: $14K · Honoraria: $3,275 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $80,398.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,189.29 |
| Food and Beverage | $15,534.99 |
| Travel and Lodging | $14,229.23 |
| Honoraria | $3,275.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $138,310.32 | 2019-2025 | Erleada, Akeega, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $88,452.48 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $37,932.21 | 2019-2025 | Provenge |
| Pfizer INC. | $32,455.22 | 2019-2025 | |
| Sn Holdings, LLC | $31,859.00 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $30,973.25 | 2020-2025 | Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $26,452.13 | 2019-2025 | Lynparza, Keytruda |
| Novartis Pharmaceuticals Corporation | $23,329.45 | 2021-2025 | Pluvicto |
| Blue Earth Diagnostics | $19,187.76 | 2019-2024 | |
| Abbvie INC. | $18,616.57 | 2019-2023 | |
| Tolmar Pharmaceuticals, INC. | $17,664.10 | 2019-2022 | |
| Urogpo LLC | $14,583.57 | 2019-2020 | |
| Astellas Pharma US INC | $11,621.51 | 2019-2025 | Xtandi |
| Progenics Pharmaceuticals, INC. | $10,566.27 | 2021-2025 | Pylarify |
| Johnson & Johnson Health Care Systems INC. | $7,865.00 | 2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $6,600.75 | 2019-2020 | |
| Astellas Pharma Global Development | $5,850.00 | 2019-2024 | Xtandi |
| Siemens Medical Solutions USA, INC. | $4,938.80 | 2024 | Biograph Horizon-3r |
| Janssen Scientific Affairs, LLC | $4,458.58 | 2019-2025 | Erleada |
| Foundation Medicine, INC. | $3,527.80 | 2019-2022 | |
| Genzyme Corporation | $2,570.75 | 2019 | |
| Photocure INC | $2,250.00 | 2022 | |
| Myriad Genetic Laboratories, INC. | $1,409.69 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $1,046.00 | 2023-2025 | Orgovyx, Gemtesa |
| Accord Healthcare, INC. | $1,030.69 | 2021-2025 | |
| Urogen Pharma, INC. | $807.14 | 2021-2025 | Jelmyto |
| Intuitive Surgical, INC. | $527.21 | 2019-2022 | |
| Myovant Sciences INC. | $419.81 | 2021-2022 | |
| Boston Scientific Corporation | $358.97 | 2022-2025 | Spaceoar Vue System - 10ml, Ams 700 |
| Ferring Pharmaceuticals INC. | $277.48 | 2019-2025 | Adstiladrin |
| Histosonics, INC. | $254.73 | 2025 | |
| Medtronic, INC. | $245.47 | 2021-2024 | Interstim |
| Immunitybio, INC. | $237.44 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $226.12 | 2019-2024 | Xiaflex |
| Sun Pharmaceutical Industries INC. | $224.08 | 2019-2025 | |
| Allergan, INC. | $187.13 | 2019-2021 | |
| Coloplast Corp | $164.30 | 2024 | |
| Intrinsiq Specialty Solutions, INC. | $155.64 | 2025 | |
| Teleflex LLC | $138.74 | 2022 | |
| Janssen Global Services, LLC | $131.63 | 2024 | Erleada |
| Amgen INC. | $129.52 | 2019-2023 | Xgeva |
| Sight Sciences, INC. | $103.99 | 2024 | Omni Surgical System |
| Philips North America LLC | $103.09 | 2023 | |
| Medtronic USA, INC. | $91.77 | 2019 | |
| Urovant Sciences INC | $89.37 | 2021-2022 | |
| Antares Pharma, INC. | $87.53 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| E.R. Squibb & Sons, L.L.C. | $75.06 | 2022-2025 | Opdivo |
| Verity Pharmaceuticals INC. | $66.58 | 2022-2025 | Trelstar |
| Palette Life Sciences, INC. | $60.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $55.59 | 2019 | |
| Endo USA, INC. | $34.24 | 2024-2025 | Xiaflex, Aveed |
| Profound Medical Corp. | $32.47 | 2025 | Tulsa-Pro |
| Convatec INC. | $29.04 | 2021 | |
| Olympus America INC. | $20.41 | 2023 | Itind System |
| Rochester Medical Corporation | $18.94 | 2021 | |
| Travere Therapeutics, INC. | $18.90 | 2019 | |
| Bioprotect Medical, INC. | $18.67 | 2025 | Bioprotect Balloon Implant System |
| Caris Mpi, INC. | $18.22 | 2025 | Mi Cancer Seek |
| Ethicon US, LLC | $16.24 | 2023 | Stratafix |
| Civco Medical Instruments | $16.06 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,399.67 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Lowentritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.